Related Experiment Video
Updated: Nov 1, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Prenatal Methamphetamine Exposure: Effects on Child Development–A Systematic Review
Lorenz Harst1, Stefanie Deckert, Frederik Haarig
1Center for Evidence-based Healthcare, University Hospital Dresden, Dresden, Germany; Division of Neonatology and Pediatric Intensive Care Medicine, Department of Pediatrics, University Hospital Dresden, Dresden, Germany; Center for Feto-Neonatal Health, University Hospital Dresden, Dresden, Germany.
Insights
Prenatal methamphetamine exposure (PME) in newborns is linked to lower birth weight and developmental issues. Early intervention and prevention are crucial for affected families.
Area of Science:
- Perinatal Medicine
- Developmental Psychology
- Public Health
Background:
- Methamphetamine use prevalence in Germany is 1.9% among 15-34 year olds.
- Increasing incidence of prenatal methamphetamine exposure (PME) in newborns.
- In 2014, Saxony reported 4 PME cases per 1000 live births.
Purpose of the Study:
- To systematically review the effects of PME on neonatal health and long-term child development.
- To assess the methodological quality of observational studies with control groups.
Main Methods:
- Systematic review of publications from January 1990 to November 2019.
- Inclusion of observational studies with control groups.
- Meta-analysis of data from 4446 mother-child pairs with PME and 43,778 controls.
Main Results:
- PME associated with lower birth weight, shorter body length, and smaller head circumference.
- Developmental differences persist into toddler years.
- Increased psychological and neurocognitive abnormalities in PME children, exacerbated by adverse environments.
Conclusions:
- Early, interdisciplinary treatment for mothers, children, and families affected by PME is essential.
- Structured preventive measures for methamphetamine use are critical.
Background:
In Germany, the 12-month prevalence of methamphetamine use among persons aged 15 to 34 is 1.9%. An increasing number of newborns are being born after a prenatal methamphetamine exposure (PME). In 2014, in the German state of Saxony, approximately four out of 1000 newborns were affected.
Methods:
This systematic review (Prospero registration number CRD42017060536) includes publications that were published between January 1990 and November 2019. The purpose was to determine the effects of PME on the peri- and neonatal condition of the affected children and on their further long-term development. Observational studies with a control group were included in the review and examined for their methodological quality.
Results:
31 publications, which dealt with two prospective and six retrospective cohort studies, were included in the review. The studies involved a total of 4446 mother-child pairs with PME, compared with 43 778 pairs without PME. A metaanalysis revealed that PME was associated with, among other findings, lower birth weight (SMD = -0.348; 95% confidence interval [-0.777; 0.081]), shorter body length (SMD= -0.198 [-0.348; -0.047]), and smaller head circumference (SMD= -0.479 [-1.047; 0.089]). Some differences between the groups with and without PME persist into the toddler years. Moreover, children with PME much more commonly display psychological and neurocognitive abnormalities, which are more severe in children growing up in problematic surroundings (discord, violence, poverty, low educational level of the parent or caregiver). A limitation of this review is that not all studies employed an objective or quantitative measure of methamphet - amine use.
Conclusion:
The documented effects of PME on child development necessitate early treatment of the affected expectant mothers, children, and families. Emphasis should be placed on structured and interdisciplinary preventive measures for methamphetamine use.
More Related Videos
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Teratogenicity

